Clinical trial
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study…
NCT00382148 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00382148 |
|---|---|
| Title | A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g |
| Official title | A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS) |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peanut Hypersensitivity |
| Intervention type | Drug |
| Interventions | omalizumab |
| Enrollment | 10 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2008 |
| First posted | Sep 28, 2006 |
| Last update posted | Dec 15, 2009 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: